Troels Boldt Rømer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Troels Boldt Rømer has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Michael Erickson Benros
University of Copenhagen
7 shared publications - Hans Heugh Wandall
University of Copenhagen
3 shared publications Rune Haubo Bojesen Christensen
Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
3 shared publications- Asha M. Rudjord-Levann
Copenhagen Center for Glycomics, Institute of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Ieva Bagdonaite
Copenhagen Center for Glycomics, Institute of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Mikkel Koed Møller Aasted
Department of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark
2 shared publications
Latest Publications
- 7 October 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-2
Lessons in translation: (immuno)psychiatry need not reinvent the wheel
- 7 October 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-2
Lessons in translation: (immuno)psychiatry need not reinvent the wheel
- Open Access
- 10 March 2026
- Published by BMJ in BMJ Mental Health
- Vol. 29 (1) , e302194
Levels of evidence supporting American, European and international guidelines in psychiatry, 2014–2024: a systematic review with quantitative synthesis
Question: To what extent are psychiatry guidelines supported by high-level evidence? Study selection and analysis: Guidelines from the American Psychiatric Association, European Psychiatric Association, WHO and World Federation of Societies for Biological Psychiatry (2014–2024) were selected. Recommendations were graded by guideline authors’ levels of evidence (LOE) appraisal (standardised to the Grading of Recommendations, Assessment, Development and Evaluations framework (high, moderate, low, very low)) and by the highest-level study referenced (meta-analysis, randomised controlled trial (RCT), observational study, expert opinion, etc.). Findings: 24 guidelines, containing 545 recommendations, were included. Of 82 guidelines screened, 29 (35%) had not been updated in a decade. 63 (11.6%) recommendations were rated by guideline authors as based on high LOE. The proportion was the highest for pharmacotherapies (41/281 (14.6%)) and the lowest for somatic assessment (0/13 (0%)). The proportion of high LOE recommendations varied between publishers (European Psychiatric Association: 20 %, WHO: 1.6 %). For high LOE recommendations, only those concerning pharmacotherapies cited meta-analyses based on double-blind studies using adequate controls. A large proportion (n=241 (44.2%)) of recommendations cited either a meta-analysis of RCTs (n=155 (28.4%)) or ≥two RCTs (n=86 (15.8 %)). There were few recommendations primarily addressing self-harm (n=2), autism (n=3), attention-deficit/hyperactivity disorder (n=3), prevention (n=3), patient involvement (n=3) or discontinuation (n=6). Conclusions: Clinical guidelines in psychiatry frequently cite RCTs, but the evidence is often downgraded by guideline authors, highlighting the need for better quality trials. LOE varies across areas, with pharmacotherapies supported by the highest quality evidence. Organisations should commit to a timely update of guidelines covering all areas of psychiatry.
- 10 March 2026
- Published by BMJ in BMJ Mental Health
- Vol. 29 (1) , e302194
Open AccessLevels of evidence supporting American, European and international guidelines in psychiatry, 2014–2024: a systematic review with quantitative synthesis
Question: To what extent are psychiatry guidelines supported by high-level evidence? Study selection and analysis: Guidelines from the American Psychiatric Association, European Psychiatric Association, WHO and World Federation of Societies for Biological Psychiatry (2014–2024) were selected. Recommendations were graded by guideline authors’ levels of evidence (LOE) appraisal (standardised to the Grading of Recommendations, Assessment, Development and Evaluations framework (high, moderate, low, very low)) and by the highest-level study referenced (meta-analysis, randomised controlled trial (RCT), observational study, expert opinion, etc.). Findings: 24 guidelines, containing 545 recommendations, were included. Of 82 guidelines screened, 29 (35%) had not been updated in a decade. 63 (11.6%) recommendations were rated by guideline authors as based on high LOE. The proportion was the highest for pharmacotherapies (41/281 (14.6%)) and the lowest for somatic assessment (0/13 (0%)). The proportion of high LOE recommendations varied between publishers (European Psychiatric Association: 20 %, WHO: 1.6 %). For high LOE recommendations, only those concerning pharmacotherapies cited meta-analyses based on double-blind studies using adequate controls. A large proportion (n=241 (44.2%)) of recommendations cited either a meta-analysis of RCTs (n=155 (28.4%)) or ≥two RCTs (n=86 (15.8 %)). There were few recommendations primarily addressing self-harm (n=2), autism (n=3), attention-deficit/hyperactivity disorder (n=3), prevention (n=3), patient involvement (n=3) or discontinuation (n=6). Conclusions: Clinical guidelines in psychiatry frequently cite RCTs, but the evidence is often downgraded by guideline authors, highlighting the need for better quality trials. LOE varies across areas, with pharmacotherapies supported by the highest quality evidence. Organisations should commit to a timely update of guidelines covering all areas of psychiatry.
- Open Access
- 25 August 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-18
The DEXA-PSYCH Study—dexamethasone for moderate-to-severe depression: study protocol for a double-blind, randomized, parallel-group, placebo-controlled trial
Globally, depression represents one of the leading causes of years lived with disability. The effects of current pharmacological treatments are small-to-moderate and often delayed by weeks. Immunological disturbances have been associated with depression and meta-analyses have suggested that anti-inflammatory agents have moderate-to-large anti-depressant effects. The largest effects were reported for glucocorticoids. However, previous trials were too small to legitimize standard use of glucocorticoids as add-on treatment in depression. The purpose of the DEXA-PSYCH study is to investigate the effect and safety of short-term, oral dexamethasone compared to placebo as add-on therapy in moderate-to-severe depression. The DEXA-PSYCH trial is an investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group superiority trial. Three-hundred participants meeting criteria for moderate-to-severe depression will be randomized in a 1:1 ratio to 1 week of either dexamethasone (4 mg/day for 4 days, subsequently 2 mg/day for 3 days) or placebo as add-on treatment to treatment as usual. Both in- and out-patients are eligible. Exclusion criteria include, but are not limited to, psychotic disorders, bipolar disorder, and diabetes. The primary outcome is change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score on day 7 and will be analyzed through a Mixed Model for Repeated Measurements (MMRM) in an intention-to-treat analysis. Key secondary outcomes include response and remission rates, efficacy 3 weeks after the intervention, effects on quality of life, and safety outcomes. Other secondary outcomes include overall functioning, fatigue, anxiety, labor-market affiliation, and associations between inflammatory biomarkers and treatment response. The DEXA-PSYCH trial represents the largest trial of its kind globally. If the trial confirms findings from previous, smaller studies, short-term oral dexamethasone could become an attractive augmentation strategy if acute anti-depressant effects are warranted. Dexamethasone is an off-patent, well-known drug readily repurposed for new indications. EU Clinical Trials Number 2022–501428-45–00, Registered 25th of July 2022 in the EU Clinical Trials Information System ( https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501428-45-00 ). WHO Universal Trial Identifier U1111-1280–7614.
- 25 August 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-18
Open AccessThe DEXA-PSYCH Study—dexamethasone for moderate-to-severe depression: study protocol for a double-blind, randomized, parallel-group, placebo-controlled trial
Globally, depression represents one of the leading causes of years lived with disability. The effects of current pharmacological treatments are small-to-moderate and often delayed by weeks. Immunological disturbances have been associated with depression and meta-analyses have suggested that anti-inflammatory agents have moderate-to-large anti-depressant effects. The largest effects were reported for glucocorticoids. However, previous trials were too small to legitimize standard use of glucocorticoids as add-on treatment in depression. The purpose of the DEXA-PSYCH study is to investigate the effect and safety of short-term, oral dexamethasone compared to placebo as add-on therapy in moderate-to-severe depression. The DEXA-PSYCH trial is an investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group superiority trial. Three-hundred participants meeting criteria for moderate-to-severe depression will be randomized in a 1:1 ratio to 1 week of either dexamethasone (4 mg/day for 4 days, subsequently 2 mg/day for 3 days) or placebo as add-on treatment to treatment as usual. Both in- and out-patients are eligible. Exclusion criteria include, but are not limited to, psychotic disorders, bipolar disorder, and diabetes. The primary outcome is change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score on day 7 and will be analyzed through a Mixed Model for Repeated Measurements (MMRM) in an intention-to-treat analysis. Key secondary outcomes include response and remission rates, efficacy 3 weeks after the intervention, effects on quality of life, and safety outcomes. Other secondary outcomes include overall functioning, fatigue, anxiety, labor-market affiliation, and associations between inflammatory biomarkers and treatment response. The DEXA-PSYCH trial represents the largest trial of its kind globally. If the trial confirms findings from previous, smaller studies, short-term oral dexamethasone could become an attractive augmentation strategy if acute anti-depressant effects are warranted. Dexamethasone is an off-patent, well-known drug readily repurposed for new indications. EU Clinical Trials Number 2022–501428-45–00, Registered 25th of July 2022 in the EU Clinical Trials Information System ( https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501428-45-00 ). WHO Universal Trial Identifier U1111-1280–7614.
- Open Access
- 27 August 2024
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 4 (6) , 100389
Associations Between Mental Disorders in Donors and Matched Recipients of Hematopoietic Stem Cell Transplants: A Population-Based Cohort Study
- 27 August 2024
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 4 (6) , 100389
Open AccessAssociations Between Mental Disorders in Donors and Matched Recipients of Hematopoietic Stem Cell Transplants: A Population-Based Cohort Study
- Open Access
- 2 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Glycoengineered keratinocyte library reveals essential functions of specific glycans for all stages of HSV-1 infection
Viral and host glycans represent an understudied aspect of host-pathogen interactions, despite potential implications for treatment of viral infections. This is due to lack of easily accessible tools for analyzing glycan function in a meaningful context. Here we generate a glycoengineered keratinocyte library delineating human glycosylation pathways to uncover roles of specific glycans at different stages of herpes simplex virus type 1 (HSV-1) infectious cycle. We show the importance of cellular glycosaminoglycans and glycosphingolipids for HSV-1 attachment, N-glycans for entry and spread, and O-glycans for propagation. While altered virion surface structures have minimal effects on the early interactions with wild type cells, mutation of specific O-glycosylation sites affects glycoprotein surface expression and function. In conclusion, the data demonstrates the importance of specific glycans in a clinically relevant human model of HSV-1 infection and highlights the utility of genetic engineering to elucidate the roles of specific viral and cellular carbohydrate structures.
- 2 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Open AccessGlycoengineered keratinocyte library reveals essential functions of specific glycans for all stages of HSV-1 infection
Viral and host glycans represent an understudied aspect of host-pathogen interactions, despite potential implications for treatment of viral infections. This is due to lack of easily accessible tools for analyzing glycan function in a meaningful context. Here we generate a glycoengineered keratinocyte library delineating human glycosylation pathways to uncover roles of specific glycans at different stages of herpes simplex virus type 1 (HSV-1) infectious cycle. We show the importance of cellular glycosaminoglycans and glycosphingolipids for HSV-1 attachment, N-glycans for entry and spread, and O-glycans for propagation. While altered virion surface structures have minimal effects on the early interactions with wild type cells, mutation of specific O-glycosylation sites affects glycoprotein surface expression and function. In conclusion, the data demonstrates the importance of specific glycans in a clinically relevant human model of HSV-1 infection and highlights the utility of genetic engineering to elucidate the roles of specific viral and cellular carbohydrate structures.
- 11 May 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (6) , 2277-2290
Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis
Psychotic disorders are severe mental disorders with poorly understood etiology. Biomarkers in the cerebrospinal fluid (CSF) could provide etiological clues and diagnostic tools for psychosis; however, an unbiased overview of CSF alterations in individuals with psychotic disorders is lacking. The objective of this study was to summarize all quantifiable findings in CSF from individuals with psychotic disorders compared to healthy controls (HC). Studies published before January 25th, 2023 were identified searching PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov, and PsycINFO. Screening, full-text review, data extraction, and risk of bias assessments were performed by two independent reviewers following PRISMA guidelines. Findings in patients and healthy controls were compared and summarized using random-effects analyses and assessment of publication bias, subgroup and sensitivity analyses were performed. 145 studies, covering 197 biomarkers, were included, of which 163 biomarkers have not previously been investigated in meta-analyses. All studies showed some degree of bias. 55 biomarkers measured in CSF were associated with psychosis and of these were 15 biomarkers measured in ≥2 studies. Patients showed increased levels of noradrenaline (standardized mean difference/SMD, 0.53; 95% confidence interval/CI, 0.16 to 0.90) and its metabolite 3-methoxy-4-hydroxyphenylglycol (SMD, 0.30; 95% CI: 0.05 to 0.55), the serotonin metabolite 5-hydroxyindoleacetic acid (SMD, 0.11; 95% CI: 0.01 to 0.21), the pro-inflammatory neurotransmitter kynurenic acid (SMD, 1.58; 95% CI: 0.34 to 2.81), its precursor kynurenine (SMD,0.99; 95% CI: 0.60 to 1.38), the cytokines interleukin-6 (SMD, 0.58; 95% CI: 0.39 to 0.77) and interleukin-8 (SMD, 0.43; 95% CI: 0.24 to 0.62), the endocannabinoid anandamide (SMD, 0.78; 95% CI: 0.53 to 1.02), albumin ratio (SMD, 0.40; 95% CI: 0.08 to 0.72), total protein (SMD, 0.29; 95% CI: 0.16 to 0.43), immunoglobulin ratio (SMD, 0.45; 95% CI: 0.06 to 0.85) and glucose (SMD, 0.48; 95% CI: 0.01 to 0.94). Neurotensin (SMD, −0.67; 95% CI: −0.89 to −0.46) and γ-aminobutyric acid (SMD, −0.29; 95% CI: −0.50 to −0.09) were decreased. Most biomarkers showed no significant differences, including the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenylacetic acid. These findings suggest that dysregulation of the immune and adrenergic system as well as blood-brain barrier dysfunction are implicated in the pathophysiology of psychotic disorders.
- 11 May 2023
- Published by Springer Nature in Molecular Psychiatry
- Vol. 28 (6) , 2277-2290
Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis
Psychotic disorders are severe mental disorders with poorly understood etiology. Biomarkers in the cerebrospinal fluid (CSF) could provide etiological clues and diagnostic tools for psychosis; however, an unbiased overview of CSF alterations in individuals with psychotic disorders is lacking. The objective of this study was to summarize all quantifiable findings in CSF from individuals with psychotic disorders compared to healthy controls (HC). Studies published before January 25th, 2023 were identified searching PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov, and PsycINFO. Screening, full-text review, data extraction, and risk of bias assessments were performed by two independent reviewers following PRISMA guidelines. Findings in patients and healthy controls were compared and summarized using random-effects analyses and assessment of publication bias, subgroup and sensitivity analyses were performed. 145 studies, covering 197 biomarkers, were included, of which 163 biomarkers have not previously been investigated in meta-analyses. All studies showed some degree of bias. 55 biomarkers measured in CSF were associated with psychosis and of these were 15 biomarkers measured in ≥2 studies. Patients showed increased levels of noradrenaline (standardized mean difference/SMD, 0.53; 95% confidence interval/CI, 0.16 to 0.90) and its metabolite 3-methoxy-4-hydroxyphenylglycol (SMD, 0.30; 95% CI: 0.05 to 0.55), the serotonin metabolite 5-hydroxyindoleacetic acid (SMD, 0.11; 95% CI: 0.01 to 0.21), the pro-inflammatory neurotransmitter kynurenic acid (SMD, 1.58; 95% CI: 0.34 to 2.81), its precursor kynurenine (SMD,0.99; 95% CI: 0.60 to 1.38), the cytokines interleukin-6 (SMD, 0.58; 95% CI: 0.39 to 0.77) and interleukin-8 (SMD, 0.43; 95% CI: 0.24 to 0.62), the endocannabinoid anandamide (SMD, 0.78; 95% CI: 0.53 to 1.02), albumin ratio (SMD, 0.40; 95% CI: 0.08 to 0.72), total protein (SMD, 0.29; 95% CI: 0.16 to 0.43), immunoglobulin ratio (SMD, 0.45; 95% CI: 0.06 to 0.85) and glucose (SMD, 0.48; 95% CI: 0.01 to 0.94). Neurotensin (SMD, −0.67; 95% CI: −0.89 to −0.46) and γ-aminobutyric acid (SMD, −0.29; 95% CI: −0.50 to −0.09) were decreased. Most biomarkers showed no significant differences, including the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenylacetic acid. These findings suggest that dysregulation of the immune and adrenergic system as well as blood-brain barrier dysfunction are implicated in the pathophysiology of psychotic disorders.
- Open Access
- 27 March 2023
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 111, 1-3
The discovery of a fourth meninges: Potential implications for brain disorders
- 27 March 2023
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 111, 1-3
Open AccessThe discovery of a fourth meninges: Potential implications for brain disorders
- Open Access
- 22 September 2021
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 144 (6) , 553-562
Psychiatric Admissions, Referrals, and Suicidal Behavior Before and During the COVID‐19 Pandemic in Denmark: A Time‐Trend Study
Objective: To assess the patterns in psychiatric admissions, referrals, and suicidal behavior before and during the COVID‐19 pandemic.Methods: This study utilized health records from hospitals and Emergency Medical Services (EMS) covering 46% of the Danish population (n = 2,693,924). In a time‐trend study, we compared the number of psychiatric in‐patients, referrals to mental health services and suicidal behavior in years prior to the COVID‐19 pandemic to levels during the first lockdown (March 11 – May 17, 2020), inter‐lockdown period (May 18 – December 15, 2020), and second lockdown (December 16, 2020 – February 28, 2021).Results: During the pandemic, the rate of psychiatric in‐patients declined compared to pre‐pandemic levels (RR = 0.95, 95% CI = 0.94 – 0.96, p < 0.01), with the largest decrease of 19% observed three weeks into the first lockdown. Referrals to mental health services were not significantly different (RR = 1.01, 95% CI = 0.92 – 1.10, p = 0.91) during the pandemic; neither was suicidal behavior among hospital contacts (RR = 1.04, 95% CI = 0.94 – 1.14, p = 0.48) nor EMS contacts (RR = 1.08, 95% CI = 1.00 – 1.18, p = 0.06). Similar trends were observed across nearly all age groups, sexes, and types of mental disorders examined. In the age group p < 0.01) was observed during the pandemic; however, this did not exceed the pre‐pandemic, upwards trend in psychiatric hospitalizations in the age group p = 0.78).Conclusion: The COVID‐19 pandemic has been associated with a decrease in psychiatric hospitalizations, while no significant change was observed in referrals to mental health services and suicidal behavior. Psychiatric hospitalizations among children and adolescents increased during the pandemic; however, this appears to be a continuation of a pre‐pandemic trend.
- 22 September 2021
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 144 (6) , 553-562
Open AccessPsychiatric Admissions, Referrals, and Suicidal Behavior Before and During the COVID‐19 Pandemic in Denmark: A Time‐Trend Study
Objective: To assess the patterns in psychiatric admissions, referrals, and suicidal behavior before and during the COVID‐19 pandemic.Methods: This study utilized health records from hospitals and Emergency Medical Services (EMS) covering 46% of the Danish population (n = 2,693,924). In a time‐trend study, we compared the number of psychiatric in‐patients, referrals to mental health services and suicidal behavior in years prior to the COVID‐19 pandemic to levels during the first lockdown (March 11 – May 17, 2020), inter‐lockdown period (May 18 – December 15, 2020), and second lockdown (December 16, 2020 – February 28, 2021).Results: During the pandemic, the rate of psychiatric in‐patients declined compared to pre‐pandemic levels (RR = 0.95, 95% CI = 0.94 – 0.96, p < 0.01), with the largest decrease of 19% observed three weeks into the first lockdown. Referrals to mental health services were not significantly different (RR = 1.01, 95% CI = 0.92 – 1.10, p = 0.91) during the pandemic; neither was suicidal behavior among hospital contacts (RR = 1.04, 95% CI = 0.94 – 1.14, p = 0.48) nor EMS contacts (RR = 1.08, 95% CI = 1.00 – 1.18, p = 0.06). Similar trends were observed across nearly all age groups, sexes, and types of mental disorders examined. In the age group p < 0.01) was observed during the pandemic; however, this did not exceed the pre‐pandemic, upwards trend in psychiatric hospitalizations in the age group p = 0.78).Conclusion: The COVID‐19 pandemic has been associated with a decrease in psychiatric hospitalizations, while no significant change was observed in referrals to mental health services and suicidal behavior. Psychiatric hospitalizations among children and adolescents increased during the pandemic; however, this appears to be a continuation of a pre‐pandemic trend.
- 15 September 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (9) , 1239-1250
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin
Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAcα-Ser/Thr) and STn (Neu5Acα2–6GalNacα-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development. Methods We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment. Results The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observed in colorectal (80%, n = 140) and pancreatic (56%, n = 108) tumours. We observed no truncated O-glycans in mesenchymal tumours (n = 32) and low expression of Tn (5%, n = 87) and STn (1%, n = 75) in CNS tumours. No Tn-antigen was found in normal tissue (n = 124) while STn was occasionally observed in healthy gastrointestinal tissue. Surface expression of Tn-antigen was identified across several cancers. Tn and STn expression decreased with tumour grade, but not with cancer stage. Numerous xenografts maintained Tn expression. Conclusions Surface expression of truncated O-glycans is limited to cancers of epithelial origin, making Tn and STn attractive immunological targets in the treatment of human carcinomas.
- 15 September 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (9) , 1239-1250
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin
Background Novel immunotherapies targeting cancer-associated truncated O-glycans Tn (GalNAcα-Ser/Thr) and STn (Neu5Acα2–6GalNacα-Ser/Thr) are promising strategies for cancer treatment. However, no comprehensive, antibody-based mapping of truncated O-glycans in tumours exist to guide drug development. Methods We used monoclonal antibodies to map the expression of truncated O-glycans in >700 tissue cores representing healthy and tumour tissues originating from breast, colon, lung, pancreas, skin, CNS and mesenchymal tissue. Patient-derived xenografts were used to evaluate Tn expression upon tumour engraftment. Results The Tn-antigen was highly expressed in breast (57%, n = 64), colorectal (51%, n = 140) and pancreatic (53%, n = 108) tumours, while STn was mainly observed in colorectal (80%, n = 140) and pancreatic (56%, n = 108) tumours. We observed no truncated O-glycans in mesenchymal tumours (n = 32) and low expression of Tn (5%, n = 87) and STn (1%, n = 75) in CNS tumours. No Tn-antigen was found in normal tissue (n = 124) while STn was occasionally observed in healthy gastrointestinal tissue. Surface expression of Tn-antigen was identified across several cancers. Tn and STn expression decreased with tumour grade, but not with cancer stage. Numerous xenografts maintained Tn expression. Conclusions Surface expression of truncated O-glycans is limited to cancers of epithelial origin, making Tn and STn attractive immunological targets in the treatment of human carcinomas.
- Open Access
- 1 September 2020
- Published by Elsevier in Developmental Cell
- Vol. 54 (5) , 669-684.e7
Essential Functions of Glycans in Human Epithelia Dissected by a CRISPR-Cas9-Engineered Human Organotypic Skin Model
- 1 September 2020
- Published by Elsevier in Developmental Cell
- Vol. 54 (5) , 669-684.e7
Open AccessEssential Functions of Glycans in Human Epithelia Dissected by a CRISPR-Cas9-Engineered Human Organotypic Skin Model